Stockreport

Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Enzo Biochem, Inc. ($0.01 Par Value)  (ENZ) 
Last enzo biochem, inc. ($0.01 par value) earnings: 12/7 04:10 pm Check Earnings Report
US:NYSE Investor Relations: enzo.com/corporate/investor-information
PDF NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced [Read more]